tmem107 Antibody

What is TMEM107 and what cellular structures should researchers target for detection?

TMEM107 is a multi-pass transmembrane protein that localizes primarily to the transition zone of cilia, serving as a functional bridge between the basal body and ciliary axoneme. When performing immunostaining experiments, researchers should focus on:

• The ciliary transition zone where TMEM107 recruits ciliopathy proteins to specific subdomains

• Cytoplasmic regions in non-ciliated cells (as shown in NSCLC studies)

• The membrane of ciliated cells where it participates in the tectonic-like complex (also named B9 complex)

For optimal detection, super-resolution microscopy techniques like STED or dSTORM are recommended for visualizing TMEM107's periodic localization within the transition zone, as conventional fluorescence microscopy may not resolve its precise subdomain organization .

How should researchers validate TMEM107 antibody specificity for reliable experimental results?

To ensure experimental validity, implement the following multi-step validation process:

• Peptide competition assays: Pre-incubate the antibody with the immunogenic peptide (e.g., the synthesized peptide derived from human TMEM107 sequence SGVSMFNSTQSLISIGAHCSASV) to confirm signal suppression

• Genetic controls: Include TMEM107 knockdown or knockout samples alongside wildtype controls to verify signal reduction

• Cross-reactivity assessment: Test against a protein array (similar to the 364 human recombinant protein fragments used to validate commercial antibodies)

• Orthogonal method validation: Compare antibody-based detection with mRNA expression data from the same samples

• Multiple antibody comparison: When possible, compare results using antibodies targeting different epitopes of TMEM107

This comprehensive validation approach minimizes the risk of non-specific binding and false-positive results in your experimental system.

What are the recommended protocols for TMEM107 detection in different tissue preparations?

Different experimental contexts require specific optimization strategies:

For paraffin-embedded tissues:

• Antigen retrieval is critical (heat-induced epitope retrieval in citrate buffer pH 6.0)

• Recommended antibody dilution: 1:20 to 1:50 for immunohistochemistry

• Counterstain nuclei with hematoxylin for better visualization of cellular context

• Incubation time: 12-16 hours at 4°C yields optimal signal-to-noise ratio

For frozen tissue sections:

• Fix with 4% paraformaldehyde for 10 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 for 5 minutes

• Blocking with 5% normal serum from the same species as the secondary antibody

• Longer primary antibody incubation times (16-24 hours) generally improve signal intensity

For cultured cells:

• For immunofluorescence in cultured epithelial cells, methanol fixation often preserves ciliary structures better than paraformaldehyde

• Co-staining with basal body markers (e.g., γ-tubulin) helps define the precise localization of TMEM107 at the transition zone

These protocols should be further optimized for each specific experimental system .

How can researchers use TMEM107 antibodies to investigate ciliary transition zone architecture?

The ciliary transition zone represents a complex protein network that functions as a diffusion barrier. To effectively study TMEM107's role in this structure:

• Layer-specific co-localization analysis: TMEM107 occupies an intermediate layer of the transition zone-localized MKS module. Design experiments with co-staining for proteins from:

  • Layer 1 (MKS-5/RPGRIP1L)

  • Layer 2 (TMEM-231, MKS-2/TMEM216)

  • Layer 3 (TMEM-17, JBTS-14/TMEM237)

  • MKS-1 (unassigned layer)

• Functional diffusion barrier assessment: Use TMEM107 antibodies alongside fluorescently-tagged ciliary membrane proteins to analyze barrier function in:

  • Wild-type cells

  • TMEM107-depleted cells

  • Cells with mutations in other transition zone components

• Super-resolution analysis protocol:

  • Fix cells with glutaraldehyde/paraformaldehyde mixture

  • Apply specialized mounting media to minimize photobleaching

  • Employ STED or dSTORM imaging with appropriate fluorophore selection

  • Quantify the periodic distribution pattern of TMEM107 with respect to axonemal microtubules

This multi-faceted approach reveals both structural and functional aspects of TMEM107's role in transition zone architecture.

What are the best approaches for investigating TMEM107's protein-protein interactions?

Based on previous successful studies, implement the following methodologies:

• Co-immunoprecipitation (coIP) optimized for membrane proteins:

  • Use mild detergents (0.5-1% digitonin or 1% CHAPS) to maintain membrane protein interactions

  • Include protease inhibitors and perform at 4°C throughout

  • For TMEM107, successfully demonstrated interactions include TMEM216, TMEM231, TMEM237, and MKS1 (but not TMEM17)

• Domain-specific interaction mapping:

  • Generate constructs expressing specific domains of TMEM107 (N-terminus, transmembrane domains, C-terminus)

  • TMEM107 recruitment of TMEM-17 and TMEM-231 appears independent of its cytosolic N- and C-termini, suggesting function through transmembrane helices or interhelical linkers

• Proximity labeling approaches:

  • Use BioID or APEX2 fusion proteins to identify proximal proteins in living cells

  • This approach can reveal transient or weak interactions that may be lost during traditional coIP

• Verification in multiple cell types:

  • Test interactions in both ciliated and non-ciliated cells to assess context-dependent interactions

  • Compare interaction patterns between normal and pathological samples (e.g., NSCLC vs. normal lung tissue)

These methodologies provide complementary data on TMEM107's physical associations and functional networks.

How should researchers design experiments to study TMEM107's role in Hedgehog signaling?

TMEM107 functions in Hedgehog signaling regulation, particularly relevant to embryonic development and cancer biology. Design robust experiments using:

• Pathway activation and inhibition:

  • Establish baseline by measuring Gli1 expression (Hedgehog pathway target) in cells with normal TMEM107 levels

  • Compare with TMEM107-knockdown cells, which show upregulated Gli1 expression

  • Include Hedgehog pathway inhibitor (e.g., GANT61) as a control, which attenuates TMEM107-knockdown-induced effects

• Functional readouts:

  • Measure pathway output using Gli-responsive luciferase reporters

  • Assess cellular phenotypes associated with Hedgehog activation, including:

    • EMT markers (N-cadherin, vimentin, E-cadherin)

    • Invasion-associated proteins (MMP2, MMP9)

    • Cell migration and invasion assays

• Tissue-specific context:

  • For neural tube studies: examine ventral and intermediate neuronal cell types (where TMEM107 acts with GLI2 and GLI3)

  • For cancer studies: compare effects in NSCLC cells with varying differentiation states

• Temporal dynamics analysis:

  • Use inducible knockdown/overexpression systems to capture immediate vs. delayed effects on signaling

  • Monitor ciliary localization of Hedgehog components during pathway activation

This experimental framework provides mechanistic insights into how TMEM107 regulates Hedgehog signaling across different biological contexts.

How can TMEM107 antibodies be utilized in ciliopathy research models?

Ciliopathies represent a spectrum of genetic disorders resulting from ciliary dysfunction. To effectively study TMEM107's role:

• Model system selection and analysis:

  • C. elegans models: Utilize synthetic genetic interactions (e.g., tmem-107;nphp-4 double mutants) to analyze cilium structure defects via:

    • Dye-filling assays to assess cilium integrity

    • Transmission electron microscopy to quantify cilia truncation or absence

    • Sensory behavior assays to measure functional deficits

  • Mammalian models: Compare TMEM107 expression and localization between:

    • Wild-type tissues

    • Tissues from ciliopathy models (e.g., MKS, JBTS, NPHP)

    • Patient-derived samples when available

• Rescue experiment design:

  • Express wild-type TMEM107 in mutant backgrounds to assess functional rescue

  • Create domain-specific mutations to identify critical regions for cilium function

  • Test whether TMEM107 overexpression can compensate for deficiencies in other TZ proteins

• Developmental timing analysis:

  • Examine TMEM107 expression throughout development in ciliopathy models

  • Correlate expression patterns with the onset of specific phenotypes

  • Use conditional expression systems to determine critical developmental windows

These approaches help elucidate TMEM107's contributions to ciliopathy pathogenesis and identify potential therapeutic targets.

What methodological approaches best detect altered TMEM107 expression in cancer tissues?

TMEM107 shows reduced expression in NSCLC with prognostic implications. Implement these methodologies for comprehensive assessment:

• Quantitative expression analysis protocols:

  • Western blotting: Use 20-50μg total protein from paired tumor/normal samples

  • Immunohistochemistry: Apply 1:20-1:50 dilution on paraffin-embedded sections

  • Compare cytoplasmic staining intensity between tumor and adjacent normal tissue

• Scoring system standardization:

  • Implement semi-quantitative scoring (0-3) based on staining intensity

  • Calculate H-score (intensity × percentage of positive cells)

  • Use digital image analysis software for objective quantification

  • Always include positive and negative controls for normalization

• Correlation with clinicopathological parameters:

  • Analyze TMEM107 expression in relation to:

    • Cell differentiation (positive correlation observed)

    • Lymph node metastasis (negative correlation observed)

    • Tumor grade and stage

• Multi-marker analysis:

  • Co-stain for TMEM107 alongside:

    • EMT markers (E-cadherin, N-cadherin, vimentin)

    • Hedgehog pathway components (Gli1)

    • Invasion markers (MMP2, MMP9)

This comprehensive approach provides both quantitative data and valuable clinicopathological correlations for cancer research.

How can researchers investigate TMEM107's functional role in EMT and cancer invasion?

Evidence indicates TMEM107 inhibits EMT and invasion in NSCLC by negatively regulating Hedgehog signaling. Design functional studies using:

• Gene manipulation experiments:

  • Knockdown: Use siRNA or shRNA targeting TMEM107 in cancer cell lines

  • Overexpression: Introduce TMEM107 expression constructs in low-expressing lines

  • CRISPR/Cas9: Generate knockout cell lines for complete loss-of-function studies

• Functional assays for quantitative assessment:

  • Transwell invasion assays with Matrigel coating

  • Wound healing assays for migration assessment

  • 3D spheroid invasion models in extracellular matrix

  • In vivo metastasis assays using fluorescently labeled cells

• Molecular mechanism investigation:

  • Western blot analysis of:

    • EMT markers (E-cadherin decrease, N-cadherin/vimentin increase with TMEM107 knockdown)

    • Matrix metalloproteinases (MMP2, MMP9 increase with TMEM107 knockdown)

    • Hedgehog pathway components (Gli1 increase with TMEM107 knockdown)

• Pathway inhibition rescue experiments:

  • Treat TMEM107-knockdown cells with Hedgehog pathway inhibitor GANT61

  • Assess whether inhibitor can reverse the EMT and invasion phenotypes

  • Quantify marker expression changes by western blot and qPCR

This experimental framework elucidates the mechanistic relationship between TMEM107, Hedgehog signaling, and cancer cell behavior.

What are common technical challenges when using TMEM107 antibodies and how can they be addressed?

Researchers often encounter specific difficulties when working with TMEM107 antibodies:

• Low signal intensity challenges:

  • Problem: Weak detection due to low endogenous expression

  • Solutions:

    • Increase antibody concentration (test range from 1:20 to 1:100)

    • Extend primary antibody incubation (overnight at 4°C)

    • Use signal amplification systems (tyramide signal amplification or polymer-based detection)

    • Try different antigen retrieval methods (citrate, EDTA, or enzymatic retrieval)

• Non-specific binding issues:

  • Problem: Background signal in multiple cellular compartments

  • Solutions:

    • More stringent blocking (5-10% normal serum plus 1% BSA)

    • Include 0.1-0.3% Triton X-100 in antibody diluent

    • Pre-adsorb antibody with acetone powder from relevant tissues

    • Validate with peptide competition to identify true signal

• Ciliary structure preservation:

  • Problem: Ciliary architectures can be disrupted during processing

  • Solutions:

    • Fix samples with 2% paraformaldehyde + 0.1% glutaraldehyde

    • For cultured cells, use methanol fixation which often better preserves ciliary structures

    • Process tissues gently and minimize mechanical disruption

    • Use microwave-assisted fixation for improved preservation

• Quantification standardization:

  • Problem: Inconsistent quantification between experiments

  • Solutions:

    • Include calibration standards on each slide/blot

    • Normalize to housekeeping proteins in western blots

    • Use automated image analysis with defined thresholds

    • Report relative rather than absolute expression values

Implementing these troubleshooting strategies significantly improves detection reliability and consistency.

What experimental controls are essential when studying TMEM107 in different research contexts?

Robust experimental design requires comprehensive controls:

• Antibody validation controls:

  • Positive control: Tissues/cells known to express TMEM107 (e.g., ciliated epithelia)

  • Negative control: TMEM107 knockout or knockdown samples

  • Technical negative: Primary antibody omission

  • Peptide competition: Pre-incubation with immunizing peptide

  • Isotype control: Non-specific antibody of same isotype and concentration

• Genetic manipulation controls:

  • Non-targeting siRNA/shRNA control alongside TMEM107 knockdown

  • Empty vector control alongside TMEM107 overexpression

  • Rescue experiments with wild-type TMEM107 to confirm specificity

  • Dose-response testing for knockdown/overexpression effects

• Pathway analysis controls:

  • Hedgehog pathway activator (e.g., Smoothened agonist)

  • Hedgehog pathway inhibitor (e.g., GANT61)

  • Positive controls for EMT (TGF-β treatment)

  • Matched treatment timing and concentrations

• Data analysis controls:

  • Technical replicates (minimum triplicate)

  • Biological replicates (different passages, donors, or animal cohorts)

  • Blinded quantification to prevent observer bias

  • Appropriate statistical tests with corrections for multiple comparisons

These control strategies ensure experimental rigor and enhance data reliability across diverse research contexts.

How might TMEM107 antibodies contribute to therapeutic development research for ciliopathies and cancer?

The dual role of TMEM107 in ciliary function and cancer progression suggests several promising research directions:

• Biomarker development strategies:

  • Evaluate TMEM107 as a prognostic biomarker in NSCLC patient cohorts

  • Correlate expression levels with treatment response to standard therapies

  • Develop tissue microarray analysis protocols for high-throughput screening

  • Explore TMEM107 detection in liquid biopsies (circulating tumor cells)

• Drug screening approaches:

  • Generate reporter cell lines with TMEM107 promoter driving luciferase expression

  • Screen compound libraries for modulators of TMEM107 expression

  • Develop high-content imaging assays for TMEM107 localization

  • Test Hedgehog pathway inhibitors in combination with TMEM107 modulation

• Personalized medicine applications:

  • Stratify patients based on TMEM107 expression profiles

  • Correlate TMEM107 status with Hedgehog pathway activation

  • Test sensitivity to targeted therapies based on TMEM107 expression

  • Develop companion diagnostics for potential Hedgehog-targeting drugs

• Gene therapy considerations:

  • Design AAV vectors for TMEM107 delivery to ciliopathy models

  • Test CRISPR-based approaches for correcting TMEM107 mutations

  • Evaluate in vitro and in vivo efficacy in disease models

  • Assess off-target effects and delivery optimization

These research approaches may ultimately translate TMEM107 biology into clinical applications for both ciliopathies and cancer.

What recent methodological innovations might enhance TMEM107 research?

Several cutting-edge technologies are particularly relevant to advancing TMEM107 research:

• Single-cell analysis techniques:

  • Single-cell RNA-seq to identify cell populations with variable TMEM107 expression

  • Single-cell proteomics to correlate TMEM107 with other protein levels

  • Spatial transcriptomics to map TMEM107 expression in tissue microenvironments

  • CyTOF with metal-conjugated antibodies for multi-parameter analysis

• Advanced imaging approaches:

  • Expansion microscopy for improved resolution of ciliary transition zone

  • Lattice light-sheet microscopy for long-term live imaging of TMEM107 dynamics

  • Correlative light and electron microscopy (CLEM) to combine ultrastructural and protein localization data

  • Fluorescence correlation spectroscopy to measure TMEM107 mobility in membranes

• Organoid and 3D culture systems:

  • Airway organoids for studying TMEM107 in differentiated ciliated epithelia

  • Patient-derived cancer organoids for personalized drug testing

  • Microfluidic organ-on-chip models with cilia-dependent flow sensing

  • Co-culture systems to examine TMEM107's role in tumor-stroma interactions

• In vivo models and approaches:

  • CRISPR-engineered animal models with fluorescently tagged endogenous TMEM107

  • Conditional knockout/knockin models for tissue-specific TMEM107 manipulation

  • Intravital microscopy for real-time imaging of TMEM107-related processes

  • Patient-derived xenografts to study TMEM107's role in tumor progression

These methodological advances offer new opportunities to understand TMEM107 biology across scales from molecular interactions to organismal phenotypes.